Hemispherx Biopharma Added to Russell 2000 and 3000

Indexes Philadelphia (PROTEXT) - Hemispherx Biopharma (Amex: HEB)announced today that it has been added to the Russell 3000(R)Index effective at the close of business June 30, 1999. TheRussell 3000 measures the performance of the 3,000 largest UScompanies based on total market capitalization, which representsapproximately 98% of the investable US equity market. Hemispherx has also been added to the Russell 2000(R) Index,which measures the performance of the 2,000 smallest companies inthe Russell 3000 Index. The Russell 2000 represents approximately11% of the total market capitalization of the Russell 3000 Index.As of the latest reconstitution of the indexes, the averagemarket capitalization was approximately $592 million; the medianmarket capitalization was approximately $500 million. The largestcompany in the Russell 2000 Index had an approximate marketcapitalization of $1.4 billion. "Our inclusion in the Russell 2000 and Russell 3000 is areflection of our dynamic technologic growth," said William A.Carter, M.D., President and CEO of Hemispherx. "It is a testamentto the quality of our technology, our employees and the trust ofour shareholders that we have reached this milestone." Frank Russell Company, one of the world's leading investmentmanagement and advisory firms, provides investment advice,analytic tools and funds to institutional and individualinvestors in more than 30 countries. Russell's investmentmanagement business employs a manager-of-managers approach andhas approximately $50 billion in assets under management.Additional information on the Russell indexes can be found onRussell's Web site at http://www.russell.com. About Hemispherx: Hemispherx is a biopharmaceutical company specializing in thenew therapeutic approaches to HIV/AIDS, CFS (Chronic FatigueSyndrome) and hepatitis B/C utilizing the immune system. It hasoffices in Philadelphia, Belgium and France and new drugdevelopment facilities in the Washington D.C. area. Information contained in this news release other thanhistorical information, should be considered forward-looking andis subject to various risk factors and uncertainties. Forinstance, the strategies and operations of HEMISPHERX involverisks of competition, changing market conditions, changes in lawsand regulations affecting these industries and numerous otherfactors discussed in this release and in the Company's filingswith the Securities and Exchange Commission. Accordingly, actualresults may differ materially from those in any forward-lookingstatements. ots Original Text Service: Hemispherx Biopharma,Inc. Internet: http://www.newsaktuell.de Contact: William A.Carter, M.D., CEO & Chairman of Hemispherx Biopharma, Inc., (USA)215-988-0080; or Media - William Jenks, (USA) 212-232-2222, orfax, (USA) 212-232-3232; or Investor Relations - Sharon Will,(USA) 212-572-0762, or fax, (USA) 212-572-0764 Web site:http://www.hemispherx.com

Subscribers please note that material bearing the slug"PROTEXT" is not part of CTK's news service and is not to bepublished under the "CTK" slug. Protext is a commercial serviceproviding distribution of press releases from clients, who areidentified in the text of Protext reports and who bear fullresponsibility for their contents.

PROTEXT